Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

Stephen Brand; Eun Jung Ko; Elisabet Viayna; Stephen Thompson; Daniel Spinks; Michael Thomas; Lars Sandberg; Amanda F. Francisco; Shiromani Jayawardhana; Victoria C. Smith; Chimed Jansen; Manu De Rycker; John Thomas; Lorna MacLean; Maria Osuna-Cabello; Jennifer Riley; Paul Scullion; Laste Stojanovski; Frederick R. C. Simeons; Ola Epemolu; Yoko Shishikura; Sabrinia D. Crouch; Tania S. Bakshi; Christopher J. Nixon; Iain H. Reid; Alan P. Hill; Tim Z. Underwood; Sean J. Hindley; Sharon A. Robinson; John M. Kelly; Jose M. Fiandor; Paul G. Wyatt; Maria Marco; Timothy J. Miles; Kevin D. Read; Ian H. Gilbert

doi:10.1021/acs.jmedchem.7b00463

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

Stephen Brand, Eun Jung Ko, Elisabet Viayna, Stephen Thompson, Daniel Spinks, Michael Thomas, Lars Sandberg, Amanda F. Francisco, Shiromani Jayawardhana, Victoria C. Smith, Chimed Jansen, Manu De Rycker, John Thomas, Lorna MacLean, Maria Osuna-Cabello, Jennifer Riley, Paul Scullion, Laste Stojanovski, Frederick R. C. Simeons, Ola EpemoluYoko Shishikura, Sabrinia D. Crouch, Tania S. Bakshi, Christopher J. Nixon, Iain H. Reid, Alan P. Hill, Tim Z. Underwood, Sean J. Hindley, Sharon A. Robinson, John M. Kelly, Jose M. Fiandor, Paul G. Wyatt, Maria Marco, Timothy J. Miles (Lead / Corresponding author), Kevin D. Read (Lead / Corresponding author), Ian H. Gilbert (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

42 Citations (Scopus)

297 Downloads (Pure)

Abstract

Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America. There is an urgent need for new safer treatments because current standard therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase. Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC). Optimization of the ATC series gave improvements in potency, aqueous solubility, and metabolic stability, which combined to give significant improvements in oral exposure. Mitigation of a potential Ames and hERG liability ultimately led to two promising compounds, one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.

Original language	English
Pages (from-to)	7284-7299
Number of pages	16
Journal	Journal of Medicinal Chemistry
Volume	60
Issue number	17
Early online date	27 Aug 2017
DOIs	https://doi.org/10.1021/acs.jmedchem.7b00463
Publication status	Published - 14 Sept 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acs.jmedchem.7b00463Licence: Other

Final Published Version
© 2017 American Chemical Society. ACS Editors' Choice - This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
Final published version, 3.53 MBLicence: Other

Discovery and Development of Drug Candidates for Neglected Diseases (joint with industrial partner)
Brenk, R. (Investigator), Fairlamb, A. (Investigator), Ferguson, M. (Investigator), Field, M. (Investigator), Gilbert, I. (Investigator), Gray, D. (Investigator), Hopkins, A. (Investigator), Horn, D. (Investigator), Read, K. (Investigator), Wyatt, P. (Investigator) & van Aalten, D. (Investigator)
1/02/11 → 1/07/17
Project: Research

Gilbert, Ian
- Drug Discovery Unit - Professor/Head of the Drug Discovery Unit & Roscoe Chair in Drug Discovery
Person: Academic

Cite this

Brand, S., Ko, E. J., Viayna, E., Thompson, S., Spinks, D., Thomas, M., Sandberg, L., Francisco, A. F., Jayawardhana, S., Smith, V. C., Jansen, C., De Rycker, M., Thomas, J., MacLean, L., Osuna-Cabello, M., Riley, J., Scullion, P., Stojanovski, L., Simeons, F. R. C., ... Gilbert, I. H. (2017). Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. Journal of Medicinal Chemistry, 60(17), 7284-7299. https://doi.org/10.1021/acs.jmedchem.7b00463

@article{c8402046f3ed48e28c4e242c0c947af3,

title = "Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi",

abstract = "Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America. There is an urgent need for new safer treatments because current standard therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase. Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC). Optimization of the ATC series gave improvements in potency, aqueous solubility, and metabolic stability, which combined to give significant improvements in oral exposure. Mitigation of a potential Ames and hERG liability ultimately led to two promising compounds, one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.",

author = "Stephen Brand and Ko, {Eun Jung} and Elisabet Viayna and Stephen Thompson and Daniel Spinks and Michael Thomas and Lars Sandberg and Francisco, {Amanda F.} and Shiromani Jayawardhana and Smith, {Victoria C.} and Chimed Jansen and {De Rycker}, Manu and John Thomas and Lorna MacLean and Maria Osuna-Cabello and Jennifer Riley and Paul Scullion and Laste Stojanovski and Simeons, {Frederick R. C.} and Ola Epemolu and Yoko Shishikura and Crouch, {Sabrinia D.} and Bakshi, {Tania S.} and Nixon, {Christopher J.} and Reid, {Iain H.} and Hill, {Alan P.} and Underwood, {Tim Z.} and Hindley, {Sean J.} and Robinson, {Sharon A.} and Kelly, {John M.} and Fiandor, {Jose M.} and Wyatt, {Paul G.} and Maria Marco and Miles, {Timothy J.} and Read, {Kevin D.} and Gilbert, {Ian H.}",

note = "Funding for this work was provided by the Wellcome Trust (nos. 092340 and 100476)",

year = "2017",

month = sep,

day = "14",

doi = "10.1021/acs.jmedchem.7b00463",

language = "English",

volume = "60",

pages = "7284--7299",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "17",

}

Brand, S, Ko, EJ, Viayna, E, Thompson, S, Spinks, D, Thomas, M, Sandberg, L, Francisco, AF, Jayawardhana, S, Smith, VC, Jansen, C, De Rycker, M , Thomas, J , MacLean, L, Osuna-Cabello, M, Riley, J, Scullion, P, Stojanovski, L , Simeons, FRC, Epemolu, O, Shishikura, Y, Crouch, SD, Bakshi, TS, Nixon, CJ, Reid, IH, Hill, AP, Underwood, TZ, Hindley, SJ, Robinson, SA, Kelly, JM, Fiandor, JM, Wyatt, PG, Marco, M, Miles, TJ, Read, KD & Gilbert, IH 2017, 'Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi', Journal of Medicinal Chemistry, vol. 60, no. 17, pp. 7284-7299. https://doi.org/10.1021/acs.jmedchem.7b00463

TY - JOUR

T1 - Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

AU - Brand, Stephen

AU - Ko, Eun Jung

AU - Viayna, Elisabet

AU - Thompson, Stephen

AU - Spinks, Daniel

AU - Thomas, Michael

AU - Sandberg, Lars

AU - Francisco, Amanda F.

AU - Jayawardhana, Shiromani

AU - Smith, Victoria C.

AU - Jansen, Chimed

AU - De Rycker, Manu

AU - Thomas, John

AU - MacLean, Lorna

AU - Osuna-Cabello, Maria

AU - Riley, Jennifer

AU - Scullion, Paul

AU - Stojanovski, Laste

AU - Simeons, Frederick R. C.

AU - Epemolu, Ola

AU - Shishikura, Yoko

AU - Crouch, Sabrinia D.

AU - Bakshi, Tania S.

AU - Nixon, Christopher J.

AU - Reid, Iain H.

AU - Hill, Alan P.

AU - Underwood, Tim Z.

AU - Hindley, Sean J.

AU - Robinson, Sharon A.

AU - Kelly, John M.

AU - Fiandor, Jose M.

AU - Wyatt, Paul G.

AU - Marco, Maria

AU - Miles, Timothy J.

AU - Read, Kevin D.

AU - Gilbert, Ian H.

N1 - Funding for this work was provided by the Wellcome Trust (nos. 092340 and 100476)

PY - 2017/9/14

Y1 - 2017/9/14

N2 - Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America. There is an urgent need for new safer treatments because current standard therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase. Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC). Optimization of the ATC series gave improvements in potency, aqueous solubility, and metabolic stability, which combined to give significant improvements in oral exposure. Mitigation of a potential Ames and hERG liability ultimately led to two promising compounds, one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.

AB - Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America. There is an urgent need for new safer treatments because current standard therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase. Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC). Optimization of the ATC series gave improvements in potency, aqueous solubility, and metabolic stability, which combined to give significant improvements in oral exposure. Mitigation of a potential Ames and hERG liability ultimately led to two promising compounds, one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.

U2 - 10.1021/acs.jmedchem.7b00463

DO - 10.1021/acs.jmedchem.7b00463

M3 - Article

C2 - 28844141

SN - 0022-2623

VL - 60

SP - 7284

EP - 7299

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 17

ER -

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

Discovery and Development of Drug Candidates for Neglected Diseases (joint with industrial partner)

Profiles

Gilbert, Ian

Cite this